X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EuCorVac-19
Therapeutic Area: Infections and Infectious Diseases Product Name: EuCorVac-19
Highest Development Status: Phase I Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2021
Details:
The EuCorVac-19 under development is a safe vaccine formulated with the coronavirus spike protein using recombinant protein technology and with a potent adjuvant.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Niclosamide
Therapeutic Area: Infections and Infectious Diseases Product Name: DWRX2003
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
When injecting a single dose of DWRX2003 to hamsters as part of animal testing, a strong antiviral effect of the drug by the third day was observed and viral genome was barely found by the fifth day.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Niclosamide
Therapeutic Area: Infections and Infectious Diseases Product Name: DWRX2003
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
Details:
Daewoong plans to enter phase 2/3 trial in multiple nations before this year ends, and aims to apply for conditional approval or emergency use of the drug upon phase 2 clinical trial results.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CT-P59
Therapeutic Area: Infections and Infectious Diseases Product Name: CT-P59
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2020
Details:
The Phase I clinical trial is designed to evaluate the safety, tolerability and pharmacokinetics of CT-P59 in healthy subjects. The results demonstrated no significant drug-related adverse events, and no adverse events from the maximum tolerated dose cohort.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CT-P59
Therapeutic Area: Infections and Infectious Diseases Product Name: CT-P59
Highest Development Status: Phase I Product Type:
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
